Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
Abeona Therapeutics Inc. (ABEO)
Last abeona therapeutics inc. earnings: 3/16 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.abeonatherapeutics.com
Company Research
Source: GlobeNewswire
CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets, the Company’s autologous gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The new J-code for ZEVASKYN, J3389 (Topical administration, prademagene zamikeracel, per treatment) becomes effective on January 1, 2026. "The assignment of a unique, product-specific J-code by CMS is a major step forward in ZEVASKYN’s launch," said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. "This code will simplify claims and reimbursement processing between our qualified treatment centers and payers ac
Show less
Read more
Impact Snapshot
Event Time:
ABEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABEO alerts
High impacting Abeona Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ABEO
News
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead [Seeking Alpha]Seeking Alpha
- Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Abeona Therapeutics GAAP EPS of -$0.10 beats by $0.18 [Seeking Alpha]Seeking Alpha
ABEO
Earnings
- 11/12/25 - Beat
ABEO
Analyst Actions
- 10/13/25 - HC Wainwright
ABEO
Sec Filings
- 11/14/25 - Form 4
- 11/13/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- ABEO's page on the SEC website